Cytotoxic Property of <i>Grias neuberthii</i> Extract on Human Colon Cancer Cells: A Crucial Role of Autophagy

Guamán-Ortiz, Luis M.; Romero-Benavides, Juan C.; Suarez, Alirica I.; Torres-Aguilar, Stephania; Castillo-Veintimilla, Paola; Samaniego-Romero, Jimmy; Ortiz-Diaz, Kevin; Bailon-Moscoso, Natalia

doi:https://doi.org/10.1155/2020/1565306

Evidence-Based Complementary and Alternative Medicine

On this page

Abstract Introduction Materials and Methods Results and Discussion Conclusions Data Availability Conflicts of Interest Authors’ Contributions Acknowledgments Supplementary Materials References Copyright Related Articles

Research Article | Open Access

Volume 2020 | Article ID 1565306 | https://doi.org/10.1155/2020/1565306

Cytotoxic Property of Grias neuberthii Extract on Human Colon Cancer Cells: A Crucial Role of Autophagy

Luis M. Guamán-Ortiz,¹Juan C. Romero-Benavides,²Alirica I. Suarez,^2,3Stephania Torres-Aguilar,¹Paola Castillo-Veintimilla,^2,4Jimmy Samaniego-Romero,¹Kevin Ortiz-Diaz,¹and Natalia Bailon-Moscoso¹

Academic Editor: Monica Borgatti

Received28 Jun 2019

Accepted10 Mar 2020

Published01 Apr 2020

Abstract

Traditional herbal medicine has become an important alternative in the treatment of various cancer types, including colon cancer, which represents one of the main health problems around the world. Therefore, the search for new therapies to counteract this disease is very active. Grias neuberthii is an endemic plant located in the Ecuadorian Amazon region, which has been used in traditional medicine for its pharmacological properties, including its ability to inhibit tumor cell growth, although scientific studies are limited. We have analyzed the effect of this plant on two colon carcinoma cell lines, that is, RKO (normal p53) and SW613-B3 (mutated p53) cells. Among several extracts obtained from various parts of G. neuberthii plant, we identified the extract with the greatest cytotoxic potential, derived from the stem bark. The cytotoxic effect was similar on both cell lines, thus indicating that it is independent of the status of p53. However, significant differences were observed after the analysis of colony formation, with RKO cells being more sensitive than SW613-B3. No evidence for apoptotic markers was recorded; nevertheless, both cell lines showed signs of autophagy after the treatment, including increased Beclin-1 and LC3-II and decreased p62. Finally, three chemical compounds, possibly responsible for the effect observed in both cell lines, were identified: lupeol (1), 3′-O-methyl ellagic acid 4-O-β-D-rhamnopyranoside (2), and 19-α-hydroxy-asiatic acid monoglucoside (3).

1. Introduction

Colorectal cancer ranks third in terms of incidence, but second in terms of mortality. [1] Colorectal cancer is increasing in Central and South America due to an ongoing transition towards higher levels of human development. [2] Understanding the mechanisms underlying the effect of apoptotic/autophagic regulators should generate new ideas and opportunities for chemotherapeutic intervention and the potential treatment of cancer patients. [3].

Natural products continue to be an important source of leads for new medicines. Historically, natural products from plants and animals have been the source of virtually all medicinal preparations and, more recently, natural products have continued to enter clinical trials or to provide leads for compounds that have entered clinical trials. [4] The production of secondary metabolites is favored by the different microenvironments. Continental Ecuador is a region with the third-highest density of endemic plant species worldwide. It is shown in [5] that G. neuberthi (Lecythidaceae) is endemic to Colombia, Ecuador, and Peru. In accordance with the ethnomedical uses reported in various herbaria from Ecuador and bibliographical references, medicinal uses (including antitumor) described for G. neuberthii are related to the digestive system. [6, 7] The objective of this work was to study the effect of G. neuberthii extracts in human colon tumor cell lines as cytotoxic agents, understanding the mechanism responsible for inducing cell death, and determining the possible secondary metabolites involved. It is important to determine the type of cell death that natural products might be inducing and whether the activation of the p53 plays an important role in the cytotoxic effect. Thus, we have selected two colon cancer cell lines, one with normal p53 and another with mutated p53.

2. Materials and Methods

2.1. Plant Material

G. neuberthii was collected on a farm in Lumbaqui (00°01′46″ Lat. S; 77°10′24″ Long. O, 366 m.a.s.l) Sucumbios Province of Ecuador. A sample specimen (LOJA-49) was deposited in the Herbarium of Universidad Nacional de Loja, Ecuador, and identified by Xavier Cornejo and Zhofre Aguirre.

2.2. Preparation Extract

The aerial parts (leaves, stem bark, fruit, and seed) were reduced to fine particles by grinding to a suitable size and then were dried at 30°C for seven days in dryer trays with air flow.

The dried and ground aerial parts of G. neuberthii (4045 g) were macerated at room temperature for 72 h in a light-free environment, with hexane, ethyl acetate, and methanol, sequentially, with 5 L of each solvent; the procedure was repeated three times. The extracts were filtered using filter paper; all extracts were concentrated at 50 mbar and 37°C on a rotary evaporator (Buchi R210, Switzerland), and subsequently stored at 4°C and protected from light until further use.

Thin-layer chromatography using aluminum plates coated with silica gel 60 F254 (Merck, Germany) was performed on each extract.

For biological studies, stock solutions (40 mg/mL) were prepared in dimethylsulfoxide (DMSO–Sigma Aldrich, USA) and stored at −20°C until use. The aliquots were diluted to obtain the appropriate concentrations before use.

2.3. Phytochemical Screening

Phytochemical screening to test for the presence of secondary metabolites (alkaloids, terpenoids, steroids, flavonoids, tannins, saponins, and quinones) and proteins, carbohydrates, and fats and oils in the extracts was carried out using standard procedures [8].

2.4. Characterization and Identification of Secondary Metabolites

Melting points were determined using a Fisher-Johns apparatus. The ¹H and ¹³C NMR spectra were recorded at 400 MHz and 100 MHz, respectively, on Varian 400 MHz Premium Shielded Equipment (Varian, USA) using tetramethylsilane as an internal reference. CDCl₃, C₅D₅N, and DMSO-d₆ were used as solvents; chemical shifts were expressed in parts per million (ppm), and coupling constants (J) were reported in Hz.

2.5. Extraction and Isolation of Compounds

The most active extract, methanol extract of stem bark (GNSbM), was partitioned, and 30 g was dissolved in MeOH : H₂O (9 : 1) in a ratio of 1 : 20 (extract: solvent) (540 mL of MeOH and 60 mL of H₂O) and sequentially partitioned three times with 400 mL of each solvent hexane (Hex), dichloromethane (DCM), and ethyl acetate (EtOAc) using a separatory funnel at room temperature. The solvents were removed using a rotary evaporator (Buchi R210; Switzerland, Flawil) at 35°C under vacuum. From the hexane fraction (GNSbM-F-Hex), 0.1330 g was obtained. The dichloromethane fraction (GNSbM-F-DCM) yielded 2.3697 g, the ethyl acetate fraction (GNSbM-F-EtOAc) yielded 10.5817 g, and the aqueous fraction (GNSbM-F-Aq) yielded 16.8156 g.

The hexane fraction (GNSbM-F-Hex) was submitted to column chromatography, with an extract/silica ratio of 1 : 200. The column was eluted according to a gradient of increasing polarity, from DCM : MeOH : H₂O (67 : 28 : 5) to DCM : MeOH : H₂O (55 : 40 : 5), obtaining a total of 12 fractions of GNSbF-Hex (GNSbF-Hex-1–12). The GNSbF-Hex-3 fraction was purified by column chromatography, with an isocratic system of Hex : EtOAc (90 : 10) to get compound 1. The spectral properties of this compound, including ¹H-NMR and ¹³C-NMR data, were identical to those previously described in the literature for the lupeol. [9].

Lupeol (1) C₃₀H₅₀O crystals, m.p. 215–216°C. ¹H-NMR (CDCl₃, 400 MHz): δ (ppm); 4.68, 4.56 (2H, s, H-29a, 29b), 3.18 (1H, dd, J = 4.76 Hz, 11.2 Hz, H-3), 1.25, 1.02, 0.96, 0.94, 0.82, 0.78, 0.75, (each 3H, s, CH₃ × 7). ¹³C-NMR (CDCl₃, 100 MHz); δ (ppm); 38.2 (C-1), 25.3 (C-2), 79.2 (C-3), 38.7 (C-4), 55.4 (C-5), 18.5 (C-6), 34.4 (C-7), 40.9 (C-8), 50.6 (C-9), 37.3 (C-10), 21.1 (C-11), 27.6 (C-12), 39.0 (C-13), 42.9 (C-14) 27.6 (C-15), 35.7 (C-16), 42.9 (C-17), 48.5 (C-18), 48.1 (C-19), 151.1 (C-20), 29.9 (C-21), 40.2 (C-22), 28.1 (C-23), 15.5(C-24), 16.3 (C-25), 16.2 (C-26), 14.7 (C-27), 18.5 (C-28), 109.5 (C-29), 19.5 (C-30).

The ethyl acetate fraction (GNSbM-F-EtOAc) was purified by column chromatography, with an extract/silica ratio of 1 : 200. The column was eluted with DCM : MeOH : H₂O 85 : 25 : 4 obtaining a total of 11 fractions GNSbMF-EtOAc (GNSbMF-EtOAc-1-11). The fraction GNSbMF-EtOAc-2 was also purified by column chromatography, with an isocratic system of EtOAc-MeOH 90 : 10 to get compound 2, identified as 3′-O-methyl ellagic acid 4-O-β-D-rhamnopyranoside.

3′-O-Methyl ellagic acid 4-O-β-D-rhamnopyranoside (2) C₂₁H₁₈O₁₂, white amorphous powder, m.p. 248–250°C. ¹H-NMR (C₅D₅N, 400 MHz): δ (ppm) 8.58 (1H, s, H-5), 8.14 (1H, s, H-5′), 6.53 (1H, d, J = 1.5 Hz, H-1″), 4.98 (1H, br, H-2″), 4.88 (1H, d, J = 3.4 Hz, H-3″), 4.85 (1H, d, J = 3.4 Hz, H-5″), 4.51 (1H, t, J = 9.4 Hz, H-4″), 4.28 (3H, s, 3′-OCH₃), 1.76 (3H, d, J = 6.2 Hz, CH₃-6″); ¹³C NMR: (C₅D₅N, 100 MHz) δ (ppm): 113.3 (C-1), 113.3 (C-1′), 135.9 (C-2), 143.2 (C-2′), 142.7 (C-3), 139.5 (C-3′), 146.7 (C-4), 152.8 (C-4′), 111.3 (C-5), 110.7 (C-5′), 114.3 (C-6), 113.4 (C-6′), 158.8 (C-7), 158.0 (C-7′), 100.7 (C-1″), 70.0 (C-2″), 71.1 (C-3″), 72.8 (C-4″), 70.4 (C-5″), 17.2 (C-6″), 59.8 (3′-OMe).

The fraction GNSbMF-EtOAc-3 was purified by column chromatography, with an isocratic system of EtOAc : MeOH 85 : 15, to get compound 3, identified as 19-α-hydroxy-asiatic acid monoglucoside.

19-α-Hydroxy-asiatic acid monoglucoside (3) C₃₆H₅₈O₁₁, white amorphous powder, m.p. 220–221°C. ¹H-NMR (DMSO-d6, 100 MHz): δ (ppm); 5.23 (1H, d, J = 7.9 Hz, H-1′), 4.29 (1H, s, H-2), δ; 4.15 (1H, m, H-5′); 4.28–4.57 (5H, m, H-2′, H-3′, H-4′, H-6′), 3.82 (1H, d, J = 9.3 Hz, H-3), 5.23 (1H, m, H-12) 3.12 (1H, d, J = 14.3 Hz, H-18), 1.27, 1.08, 0.94, 0.65, 0.53 (each 3H, s, CH₃ × 5); ¹³C-NMR (DMSO-d6, 100 MHz); δ (ppm); 47.5 (C-1), 67.7 (C-2), 78.2 (C-3), 42.7 (C-4), 47.1 (C-5), 17.7 (C-6), 34.9 (C-7), 41.4 (C-8), 46.8 (C-9), 37.4 (C-10), 16.8 (C-11), 127.2 (C-12), 138.4 (C-13), 41.3 (C-14) 28.8 (C-15), 24.4 (C-16), 46.8 (C-17), 53.4 (C-18), 72.4 (C-19), 41.3 (C-20), 32.2 (C-21), 36.9 (C-22), 67.7 (C-23), 13.7 (C-24), 16.9 (C-25), 16.8 (C-26), 23.5 (C-27), 175.8 (C-28), 16.6 (C-29), 16.4 (C-30), 94.2 (C-1′), 74.2 (C-2′), 76.8 (C-3′), 71.8 (C-4′), 75.8 (C-5′), 69.7 (C-6′).

2.6. Cell Culture and Treatments

Two human colon carcinoma cell lines were used to analyze the antiproliferative effect of the G. neuberthii extracts: RKO and SW613-B3. Cells were grown at 37°C and 5% CO₂ atmosphere, in RPMI medium supplemented with 10% FBS (Sigma Aldrich, USA), 0.1 mg/mL penicillin, 100 UI/mL streptomycin, and 2 mM L-glutamine (all reagents were from Gibco-Thermo Fisher Scientific, USA). Twenty-four hours after seeding, cells were treated for 48 h with the G. neuberthii extracts at 50 μg/mL or increasing doses or 0.3 μg/mL Doxorubicin (Dxo–Sigma Aldrich, USA; stock solution: 2 mg/mL in water). Final concentration of DMSO, <0.2% (v/v), in the culture medium did not alter the tested activities.

2.7. Viability Assay

Different G. neuberthii extracts were evaluated on cell proliferation by the MTS metabolic viability assay, according to Guamán-Ortiz et al. (2015). [10] Briefly, 2 × 10³ cells were seeded in 96-well plates in 100 μL of medium per well and incubated for 24 h. Then, cells were treated in triplicate for 48 h either with 50 μg/mL of each extract or 0.3 μg/mL Dxo. Four hours before finishing the treatment, 20 μL of Cell Titer 96 Aqueous One Solution cell proliferation reagent (Promega, USA) was added to each well. The plates were then maintained for 4 h at 37°C; the absorbance of each sample was measured with a microplate reader (Megallan, Tecan, Switzerland) at a wavelength of 492 nm. Absorbance from control was used as reference values (100% of viability) to normalize the data of treated samples. In order to calculate the IC₅₀, the most active extracts were selected and exposed to the cells for 48 h with increasing concentrations (5–50 μg/mL) and processed as above.

2.8. Morphological Analysis

Both cell lines were exposed to the most active extract of G. neubertii (GNSbM) in order to observe the induced effect. In brief, 5 × 10⁴ cells/mL were seeded in 3.5-cm diameter Petri dishes and incubated for 24 h. Next, cells were exposed to the extract for 48 h with their representative IC₅₀ calculated. Cells were then observed using a light microscope (Axioskop 2 plus–Zeiss, Germany) equipped with a 40x objective. Images were acquired with a digital camera Basler scA1300-32 fm using its software.

2.9. Cell Cycle Analysis

Cell cycle distribution was evaluated using propidium iodide (PI, P4170, Sigma Aldrich, USA) staining processed according to the previous protocol, Bailon-Moscoso et al. [11]. In summary, cells were seeded in 6-well plates at a density of 1 × 10⁶ cells in 2 mL of medium per well and incubated for 24 h. Cells were then treated for 48 h with 20, 30, and 50 μg/mL of GNSbM extract or 0.3 μg/mL Dxo. Detached and attached cells were harvested and washed with PBS. Cell pellets were obtained and resuspended in 100 μL of PBS, fixed with absolute ethanol, and maintained at −20°C for 24 h. Cells were washed with PBS and incubated in the dark for 30 min at room temperature in the staining buffer (50 μg/mL PI, 0.1% sodium citrate, 0.1% Triton-X-100, and 100 μg/mL RNase A). Cells in the G₁, S, and G₂/M-phase were subsequently analyzed using a FACSCanto II flow cytometer (Becton Dickinson, USA). Acquired data were analyzed using DIVA and ModFit LT software (Becton Dickinson).

2.10. Cloning Assay

To evaluate the clonogenic capacity, 2.5 × 10² cells were seeded in duplicate in 6 cm diameter Petri dishes in 2 mL of medium and incubated for 24 h. Cells were then treated for 48 h with 20, 30, and 50 μg/mL of GNSbM extract or 0.3 μg/mL Dxo, washed with BPS, incubated with 2 mL of complete medium for 7 days, and then processed according to Guamán-Ortiz et al. [12]. Colony-forming ability data were expressed as a percentage relative to control.

2.11. Western Blot Analysis

To determine the induced cell death pathway, 20, 30, and 50 μg/mL of GNSbM extract were exposed on both cell lines for 48 h. Additionally, as positive controls: cells were exposed for 10 min to UV radiation (Osram, G30T8, 30W Germicidal UV-C Lamp, 254 nm) for apoptosis induction [13] or for 1 h to PBS for starvation-induced autophagy [14], before being harvested. Apoptotic and autophagic proteins were analyzed through Western Blot analysis. The methodology was applied according to Bailon-Moscoso et al. [15]. Briefly, separated proteins from a SDS-PAGE were transferred to a PVDF membrane (IPVH00010, Immobilon-P, 0.45 μm, EMD/Millipore, Billerica, Boston, MA, USA) and incubated with primary antibodies: p53 (sc-81168), Beclin-1 (sc-48341), SQSTM 1/p62 (sc-48402) (Santa Cruz Biotechnology, USA), PARP (#9542), Bax (#2774), Bcl-2 (#15071) LC3A/B (#12741), and β-Tubulin (#2128) (Cell Signaling Technology, USA), as indicated by the manufacturer for immunoblotting. Secondary antibodies, anti-mouse IgG, HRP-linked (#7076, Cell Signaling Technology, USA), and anti-rabbit IgG, HRP-linked (#7074, Cell Signaling Technology, USA), were subsequently used. Immunoreactive bands were visualized using an enhanced chemiluminescence Luminata™ Crescendo Western HRP Substrate or Luminata™ Forte Western HRP Substrate (Millipore-Merck, Germany).

2.12. Statistical Analysis

Statistical analyses were carried out in GraphPad Prism 4 (GraphPad Software, USA). All data were reported as the means ± SEM of three independently performed experiments, as detailed in each figure. The statistical significance was obtained with one-way analysis of variance (ANOVA) followed by the Dunnett posttest. A was considered to be statistically significant comparing the control to the samples.

3. Results and Discussion

3.1. Preliminary Phytochemical Study of Extracts

The phytochemical screening tests on extracts revealed the presence or absence of the main secondary metabolites and other phytochemicals based on the presence or absence of expected color changes (Table 1). The G. neuberthii fruit extracts in methanol (GNFM) are richer in secondary metabolites; the methanolic extracts of stem bark (GNSbM) contained alkaloids, flavonoids, tannins, quinones, and saponins. The highest percentage of yield was obtained from the methanol fraction of leaves GNLM (22.97%), followed by that of hexane fraction of fruit GNFH (19.6%), and methanol fraction of stem bark GNSbM (9.4%). The lowest percentage of yield was obtained from the hexane fraction of seed GNSH (0.17%). There was also variation in the physical appearance of the extracts (Supplementary Material, S1).

3.2. Cytotoxic Effect on Human Tumor Cell Lines

In order to analyze the antiproliferative effect of G. neuberthi on colon cancer cells, all the extracts obtained were then evaluated. Table 2 describes the viability percentages using 50 μg/mL of the different G. neuberthii extracts or Dxo 0.3 μg/mL on the human tumor cell lines after 48 h of treatment. Doxorubicin, an anthracycline antibiotic, has proved to induce cytotoxicity, cell cycle arrest, and apoptosis in a wide variety of tumor cell lines, including colon cancer cells; however, its clinical use is limited due its cardiotoxicity effect [16–18]. Cell growth viability was measured using the MTS assay, considering the control as 100% of viability. As expected, the SW613-B3 cell line (with p53 mutated) was more resistant to the treatment, in contrast to the RKO cell line. The extract GNSbM, whose extracting method was by maceration in methanol, demonstrated to be the most cytotoxic, with values under 20% of viability on both wt p53 RKO and SW613-B3 with mutated p53.

According to these results, the IC₅₀ was calculated from the GNSbM extract (Figure 1(a)), which was 28 and 31.8 μg/mL in SW613-B3 and RKO, respectively. As observed, after exposing to the IC₅₀ of GNSbM, that is approximately the same, both cell lines decrease in cell population, suggesting therefore that the effect observed is not dependent on p53 status.

(a)

(b)

(c)

Figure 1

GNSbM extract demonstrated to be cytotoxic on RKO and SW613-B3 cell lines. (a) Morphological changes induced after 48 h of exposure at IC₅₀ doses of the extract. Scale bar: 50 μm. (b) Cells were exposed to the extract for 48 h and formed colonies were counted based on clonogenic survival assay seven days after the treatment. The number of counted colonies was expressed as a percentage relative to control (defined as 100%). Data represented the mean ± SEM (n = 6) of three independent experiments. The tests for significance were limited to ANOVA-Dunnet posttest, , vs. control; RKO vs. SW613-B3 at IC₅₀ dose. (c) Cells were exposed to the extract for 48. (h) Percentage of cells in the G₁, S, and G₂/M-phases of the cell cycle was analyzed using a Facscanto II flow cytometer. Data were acquired and analyzed using DIVA software (Becton Dickinson). Data represented the mean ± SEM (n = 6) of three independent experiments. The tests for significance were limited to ANOVA-Dunnet posttest, for G₁, S, and G₂/M.

The marked difference between these cell lines reveals that the SW613-B3 cells have the potential for recovery after treatment because of the results observed in colony-forming ability assay, where the cells were exposed to three different doses of GNSbM, 20, 30, and 50 μg/mL. As observed in Figure 1(b), colony-forming ability decreases in a dose-dependent manner in both cell lines; however, the SW613-B3 cell line was less affected after 20 μg/mL (90%) and IC₅₀ (80%), in contrast to the RKO cell line, which was more sensitive (60%). To note, SW613-B3 cell line has demonstrated to be resistant to different treatments. [12] Nevertheless, colony-forming ability decreases dramatically in both cell lines at the higher concentration (50 μg/mL). On the other hand, p53 has a well-known role in cell cycle progression, which after transactivation induces cell cycle arrest [19, 20]; however, the statistical analysis of cell cycle distribution revealed that no significant cell cycle changes were occurring after the treatment of both wt and mutated p53 cell lines, as observed in those treated with Dxo (Figure 1(c)).

3.3. No Apoptosis Was Detected after Treatment with GNSbM

To further explore the type of cell death induced by the plant extract, both apoptosis and autophagy pathways were analyzed by Western blotting. It is also well known that p53 is involved in multiple cell death pathways, such as apoptosis and autophagy. [21, 22] In the apoptotic pathway, p53 is upregulated to transactivate and phosphorylate the Bax protein, thereby inducing the activation of the intrinsic apoptosis; at the same time Bcl-2, an antiapoptotic protein, is downregulated in the presence of p53. [22] As observed in Figures 2(a) and 2(b), no overexpression of Bax protein was detected in the RKO cell line, despite the overexpression of p53 in a dose-dependent manner; furthermore, an increase of Bcl-2 expression was detected in the Western blot assay (Figure 2(b)), although this did not reach statistical significance relative to the control (Figure 2(a)).

(a)

(b)

Figure 2

GNSbM extract induces autophagy on RKO line cell. Cells were exposed to GNSbM or UV radiation or starvation in PBS. Total protein was separated in a SDS-PAGE followed by Western blot analysis with indicated antibodies against p53, apoptotic and autophagy biomarkers, and tubulin as a loading control. (a) Quantification of the level of p53 expression and the apoptotic and autophagy biomarkers. Data represented the mean ± SEM (n = 6) of three independent experiments. The tests for significance were limited to ANOVA-Dunnet posttest: , , vs. control. (b) Western blot pictures demonstrating the effect observed in RKO cell line. Although p53 showed to be overexpressed in a dose-dependent manner, no apoptotic activity was detected, and autophagy activity was monitored after treatment.

Additionally, in the SW613-B3 cell line, the upregulation of p53 was not observed in any of the GNSbM doses used as expected (Figures 3(a) and 3(b)). In both cell lines, no proteolysis of PARP-1 protein, an apoptotic marker [23, 24], was detected after the GNSbM treatments (Figures 2 and 3), in contrast with the cleavage visible in cells exposed to UV radiation. [25].

(a)

(b)

Figure 3

GNSbM extract induces autophagy on SW613-B3 cell line. Cells were exposed to GNSbM or UV radiation or starvation in PBS. Total protein was separated in a SDS-PAGE followed by Western blot analysis with indicated antibodies against p53, apoptotic and autophagy biomarkers, and tubulin as a loading control. (a) Quantification of the level of p53 expression and the apoptotic and autophagy biomarkers. Data represented the mean ± SEM (n = 6) of three independent experiments. The tests for significance were limited to the ANOVA-Dunnet posttest: , , vs. control. (b) Western blot pictures demonstrating the effect observed in Sw613-B3 cell line. No p53 expression was observed as expected although autophagy activity was detected after treatment.

3.4. GNSbM Extract Induces Autophagy

Autophagy pathway is activated after starvation conditions [26, 27], which induces the formation of autophagic vesicles or vacuoles called autophagosomes at the level of the cytoplasm. Therefore, the presence of vacuoles in both cell lines, observed in morphological analysis (Figure 1(a)), suggested the possible activation of the autophagic pathway [12, 28]; thus, biomarkers for autophagy were evaluated. In this pathway, Bcl-2 is associated with Beclin-1. Once Beclin-1 is released, the autophagic pathway is activated [29]; LC3-I is converted into its active form LC3-II to induce the phagophore formation in the nucleation phase to enclose the obsolete proteins and organelles, tagged with p62, for degradation [30–33]. Forced autophagy could generate severe damage that ends in the death of the cell [27]. In Figures 2(b) and 3(b), an upregulation of Beclin-1 was observed in both cell lines in a dose-dependent manner, although these results did not reach statistical significance. Dissociation between Bcl-2 and Beclin-1 is necessary for the initiation of autophagy; therefore, the increase of Bcl-2 observed in the RKO cell line (Figure 2(b)) could be explained by this dissociation. Likewise, an increase in LC-3II was detected in both the RKO and SW613-B3 cell lines in a dose-dependent manner. The final step in autophagy is the degradation of charges in which p62 is involved (being also degraded). [32] As observed in both cell lines, p62 results in a decrease (Figures 2(a) and 3(a)), therefore elucidating the termination of the autophagic process and cell death pathway. Remarkably, it is possible that autophagy is playing a double role in the SW613-B3 cell line. It is well known that the autophagy mechanism is also active in tumor cell lines and has a role in survival [22, 34]; as observed in the clonogenic assay, the SW613-B3 cell line is able to recover after treatment at the IC₅₀ dose (Figure 1(b)).

3.5. Isolation and Identification of Secondary Metabolites Isolated from GNSbM

Phytochemical investigation of methanolic extract from the stem bark of G. neuberthii (GNSbM) led to the isolation and identification of three compounds identified as: lupeol (1), 3′-O-methyl ellagic acid 4-O-β-D-rhamnopyranoside (2), and 19-α-hydroxy-asiatic acid monoglucoside (3), whose structures are shown in Figure 4. The spectral properties of these known compounds, including the ¹H NMR and ¹³C NMR data, were identical to those previously described in the literature [9].

Compound 1 was crystals. Its ¹H NMR spectra in CDCl₃ showed six singlets, corresponding to tertiary methyl groups, between 0.75 and 1.02 ppm and a singlet at 1.25 ppm, typical of a methyl group in an isopropenyl system. Two olefinic protons at 4.68 and 4.56 ppm are consistent with the methylene group of the same propylenic system. The ¹³ C NMR data showed the characteristic signals of C-3 at 79.2 ppm, C-20 at 151.1 ppm, and C-29 at 109.5 ppm. [9] Compound 2 was a white amorphous powder. Its ¹H NMR spectra in deuterated pyridine showed two singlet signals at δ 8.58 and 8.14. A broad signal at 5.31 ppm suggested a structure with some hydroxyls groups, which was corroborated with the few multiplets signals typical for carbohydrate moieties between 4.53 and 5.04 ppm. Among these signals, one singlet at δ 4.28 integrating for 3H suggested a methoxy group in this compound. The broad band carbon NMR spectra showed 21 signals including 11 quaternary carbons indicating a very conjugated aromatic structure. From these signals, two were assigned to α, β-unsaturated lactone carbonyls carbons at 158.0 and 158.2 ppm. The signals corresponding to the carbohydrate, analyzed together with the proton spectra, indicated that it was the β-D-glucopiranoside. All the data obtained by NMR were ascribable to a derivative of ellagic acid. The comparison of physical and spectroscopic data [35] indicated that the isolated compound 2 was 3′-O-methyl ellagic acid 4-O-β-D-glucopyranoside. Compound 3 was a white amorphous powder. The NMR spectra were taken in deuterated DMSO, submitted to analyses. The ¹H NMR showed the resonances of five quaternary methyl groups at 0.52, 0.54, 0.94, 1.08, and 1.26 ppm, together with a methyl doublet at δ 0.86. An olefinic proton in 5.14 ppm suggested an ursane-type triterpene for the aglycone of this glycosylated compound. Few multiplets between 3.8 and 4.60 ppm were ascribable to a sugar moiety. The carbon NMR spectra analyzed with the help of DEPT experiment revealed for the aglycone triterpene 30 carbons, including six methyl groups, nine methylene groups, counting one oxygenated, seven methine groups with two oxygenated at 77.7 and 67.7 ppm, and one olefinic group at 138.4 ppm; eight quaternary carbons comprising the olefinic at 127.2 ppm, one oxygenated at 72.4 ppm, and the carboxyl ester group at 175.8 ppm. Comparative study of the resonances of the sugar indicated that it was the β-D-glucoside. The 2D experiments, COSY, HMQC, and HMBC were in agreement with the proposed structure. All the data were compared with the literature [36, 37] to finally consider this compound as 19-hydroxy-asiatic acid monoglucoside.

Regarding this, lupeol (1), 3′-O-methyl ellagic acid 4-O-β-D-rhamnopyranoside (2), and asiatic acid-β-D-glucoside (3) are reported here for the first time in this genus. For instance, lupeol has been widely reported for its anticancer effect against various cancer cells, such as oral cancer, pancreatic cancer, gallbladder cancer, prostate cancer, and colorectal cancer. [38–41] Also, asiatic acid is known to be cytotoxic to several tumor cell lines. However, asiatic acid-induced cell death was mainly apoptotic, demonstrated in colon cancer RKO cells [42, 43]. Hence, the presence of these phytochemicals in GNSbM might be synergistically responsible for the autophagy-inducing effect, as suggested by our results.

4. Conclusions

In summary, different extracts of G. neuberthii were evaluated; the one with the greatest cytotoxic effect was the so-called GNSbM, which considerably reduced cell viability in both RKO cell line, with wt p53, and SW613-B3, with mutated p53, in a dose-dependent manner after 48 h of exposure. In addition, activation of the apoptotic route was discarded and the evidence of autophagic activity was detected. Finally, three compounds were identified in this extract: lupeol, 3′-O-methyl ellagic acid 4-O-β-D-rhamnopyranoside, and asiatic acid-β-D-glucoside, which have been shown to have antitumor effects.

Data Availability

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Luis M. Guamán-Ortiz and Juan C. Romero-Benavides contributed equally to this work.

Acknowledgments

This work was supported by International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy (ECU1601 EC) and Universidad Técnica Particular de Loja (UTPL), Loja, Ecuador (PROY_CCSAL_1266). The authors want to thank Dr. A. Ivana Scovassi for her support in the observations and analysis of experimental results and reviewing the English version.

Supplementary Materials

Different parts of the G. neubetthii were macerated for 72 h in a light‐free environment with three dissolvents separately: hexano, ethyl acetate, and methanol. The extracts were concentrated at 50 mbar and 37° C on a rotary evaporator. The appearance and weight of the extracts were recorded, and the yield was calculated. (Supplementary Materials)

References

F. Bray, J. Ferlay, I. Soerjomataram et al., “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
View at: Publisher Site | Google Scholar
M. S. Sierra and D. Forman, “Cancer in central and South America: methodology,” Cancer Epidemiology, vol. 44, pp. S11–S81, 2016.
View at: Publisher Site | Google Scholar
M. C. Maiuri and G. Kroemer, “Therapeutic modulation of autophagy: which disease comes first?” Cell Death & Differentiation, vol. 26, no. 4, pp. 680–689, 2019.
View at: Publisher Site | Google Scholar
A. L. Harvey, R. Edrada-Ebel, and R. J. Quinn, “The re-emergence of natural products for drug discovery in the genomics era,” Nature Reviews Drug Discovery, vol. 14, no. 2, pp. 111–129, 2015.
View at: Publisher Site | Google Scholar
L. N. Joppa, P. Visconti, C. N. Jenkins, and S. L. Pimm, “Achieving the convention on biological diversity's goals for plant conservation,” Science, vol. 341, no. 6150, pp. 1100–1103, 2013.
View at: Publisher Site | Google Scholar
R. V. A. SALTOS, T. E. R. Vásquez, J. A. LAZO et al., “The use of medicinal plants by rural populations of the Pastaza province in the Ecuadorian Amazon,” Acta Amazonica, vol. 46, no. 4, pp. 355–366, 2016.
View at: Publisher Site | Google Scholar
P. Vásquez-Ocmín, S. Cojean, E. Rengifo et al., “Antiprotozoal activity of medicinal plants used by Iquitos-Nauta road communities in Loreto (Peru),” Journal of Ethnopharmacology, vol. 210, pp. 372–385, 2018.
View at: Publisher Site | Google Scholar
S. C. Mandal, V. Mandal, and A. K. Das, “Preface,” in Essentials of Botanical Extraction, S. C. Mandal, V. Mandal, and A. K. Das, Eds., pp. 173–185, Academic Press, Boston, MA, USA, 2015.
View at: Publisher Site | Google Scholar
A. K. Jamal, W. A. Yaacob, and L. B. Din, “A chemical study on Phyllanthus reticulatus,” Journal of Physical Science, vol. 19, pp. 45–50, 2008.
View at: Google Scholar
N. Bailón-Moscoso, J. C. Romero-Benavides, M. Sordo et al., “Phytochemical study and evaluation of cytotoxic and genotoxic properties of extracts from Clusia latipes leaves,” Revista Brasileira de Farmacognosia, vol. 26, no. 1, pp. 44–49, 2016.
View at: Publisher Site | Google Scholar
J. C. Romero-Benavides, N. Bailon-Moscoso, H. Parra-Delgado et al., “Argentatin B derivatives induce cell cycle arrest and DNA damage in human colon cancer cells through p73/p53 regulation,” Medicinal Chemistry Research, vol. 27, no. 3, pp. 834–843, 2018.
View at: Publisher Site | Google Scholar
L. M. Guamán Ortiz, A. L. Croce, F. Aredia et al., “Effect of new berberine derivatives on colon cancer cells,” Acta Biochimica et Biophysica Sinica, vol. 47, no. 10, pp. 824–833, 2015.
View at: Publisher Site | Google Scholar
C.-H. Lee, S.-B. Wu, C.-H. Hong, H.-S. Yu, and Y.-H. Wei, “Molecular mechanisms of UV-induced apoptosis and its effects on skin residential cells: the implication in UV-based phototherapy,” International Journal of Molecular Sciences, vol. 14, no. 3, pp. 6414–6435, 2013.
View at: Publisher Site | Google Scholar
Y. Stroikin, U. Johansson, S. Asplund, and K. Öllinger, “Increased resistance of lipofuscin-loaded prematurely senescent fibroblasts to starvation-induced programmed cell death,” Biogerontology, vol. 8, no. 1, pp. 43–53, 2007.
View at: Publisher Site | Google Scholar
N. Bailon-Moscoso, G. González-Arévalo, G. Velásquez-Rojas et al., PLoS One, vol. 10, Article ID e0136527, 2015.
View at: Publisher Site
C. Jiang, L. Jiang, Q. Li et al., “Pyrroloquinoline quinine ameliorates doxorubicin-induced autophagy-dependent apoptosis via lysosomal-mitochondrial axis in vascular endothelial cells,” Toxicology, vol. 425, Article ID 152238, 2019.
View at: Publisher Site | Google Scholar
Y. Frión-Herrera, D. Gabbia, A. Díaz-García, O. Cuesta-Rubio, and M. Carrara, “Chemosensitizing activity of Cuban propolis and nemorosone in doxorubicin resistant human colon carcinoma cells,” Fitoterapia, vol. 136, p. 104173, 2019.
View at: Publisher Site | Google Scholar
J. Wang, C. Hu, J. Wang et al., “Checkpoint blockade in combination with doxorubicin augments tumor cell apoptosis in osteosarcoma,” Journal for ImmunoTherapy, vol. 42, no. 9, pp. 321–330, 2019.
View at: Publisher Site | Google Scholar
D. Menendez, A. Inga, and M. A. Resnick, “The expanding universe of p53 targets,” Nature Reviews Cancer, vol. 9, no. 10, pp. 724–737, 2009.
View at: Publisher Site | Google Scholar
F. Toledo and G. M. Wahl, “Regulating the p53 pathway: in vitro hypotheses, in vivo veritas,” Nature Reviews Cancer, vol. 6, no. 12, pp. 909–923, 2006.
View at: Publisher Site | Google Scholar
M. M. Hippert, P. S. O'Toole, and A. Thorburn, “Autophagy in cancer: good, bad, or both?: figure 1,” Cancer Research, vol. 66, no. 19, pp. 9349–9351, 2006.
View at: Publisher Site | Google Scholar
L. Galluzzi, I. Vitale, S. A. Aaronson et al., “Oncogene-induced senescence and tumour control in complex biological systems,” Cell Death & Differentiation, vol. 25, pp. 486–541, 2018.
View at: Publisher Site | Google Scholar
G. Chaitanya, J. S. Alexander, and P. Babu, “PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration,” Cell Communication and Signaling, vol. 8, no. 1, p. 31, 2010.
View at: Publisher Site | Google Scholar
L. M. Luis, M. Guaman-Ortiz, V. Vincenzo Giansanti, F. Francesca Dona, and A. A. Ivana Scovassi, “Pharmacological effects of PARP inhibitors on cancer and other diseases,” Current Enzyme Inhibition, vol. 7, no. 4, pp. 244–258, 2012.
View at: Publisher Site | Google Scholar
J. Lv and Y. Xing, “Effects of UV on apoptotic factors in lens epithelial cells of an animal model,” Experimental and Therapeutic Medicine, vol. 16, pp. 2309–2312, 2018.
View at: Publisher Site | Google Scholar
L. Poillet-Perez and E. White, “Role of tumor and host autophagy in cancer metabolism,” Genes & Development, vol. 33, no. 11-12, pp. 610–619, 2019.
View at: Publisher Site | Google Scholar
F. Aredia, L. M. Guamán Ortiz, V. Giansanti, and A. I. Scovassi, “Autophagy and cancer,” Cells, vol. 1, no. 3, pp. 520–534, 2012.
View at: Publisher Site | Google Scholar
J. Kubisch, D. Türei, L. Földvári-Nagy et al., “Complex regulation of autophagy in cancer - integrated approaches to discover the networks that hold a double-edged sword,” Seminars in Cancer Biology, vol. 23, no. 4, pp. 252–261, 2013.
View at: Publisher Site | Google Scholar
X. Lv, K. Wang, W. Tang et al., “miR‐34a‐5p was involved in chronic intermittent hypoxia‐induced autophagy of human coronary artery endothelial cells via Bcl‐2/beclin 1 signal transduction pathway,” Journal of Cellular Biochemistry, vol. 120, no. 11, pp. 18871–18882, 2019.
View at: Publisher Site | Google Scholar
J. Doherty and E. H. Baehrecke, “Life, death and autophagy,” Nature Cell Biology, vol. 20, no. 10, pp. 1110–1117, 2018.
View at: Publisher Site | Google Scholar
R. Kang, H. J. Zeh, M. T. Lotze, and D. Tang, “The Beclin 1 network regulates autophagy and apoptosis,” Cell Death & Differentiation, vol. 18, no. 4, pp. 571–580, 2011.
View at: Publisher Site | Google Scholar
T. E. Rusten and H. Stenmark, “p62, an autophagy hero or culprit?” Nature Cell Biology, vol. 12, no. 3, pp. 207–209, 2010.
View at: Publisher Site | Google Scholar
R. Gómez-Sánchez, S. M. S. Yakhine-Diop, M. Rodríguez-Arribas et al., “mRNA and protein dataset of autophagy markers (LC3 and p62) in several cell lines,” Data in Brief, vol. 7, pp. 641–647, 2016.
View at: Publisher Site | Google Scholar
L. Guaman-Ortiz, M. Orellana, and E. Ratovitski, “Natural compounds as modulators of non-apoptotic cell death in cancer cells,” Current Genomics, vol. 18, no. 2, pp. 132–155, 2017.
View at: Publisher Site | Google Scholar
X.-H. Yan and Y.-W. Guo, “Two new ellagic acid glycosides from leaves of diplopanax stachyanthus,” Journal of Asian Natural Products Research, vol. 6, no. 4, pp. 271–276, 2004.
View at: Publisher Site | Google Scholar
D.-L. Cheng and X.-P. Cao, “Pomolic acid derivatives from the root of Sanguisorba officinalis,” Phytochemistry, vol. 31, no. 4, pp. 1317–1320, 1992.
View at: Publisher Site | Google Scholar
O. T. Kim, M. L. Jin, D. Y. Lee, and R. Jetter, “Characterization of the Asiatic Acid Glucosyltransferase, UGT73AH1, Involved in Asiaticoside Biosynthesis in Centella asiatica (L.) Urban,” International Journal of Molecular Sciences, vol. 18, pp. 1–11, 2017.
View at: Publisher Site | Google Scholar
H. H. Kwon, J. Y. Yoon, S. Y. Park et al., “Activity-guided purification identifies lupeol, a pentacyclic triterpene, as a therapeutic agent multiple pathogenic factors of acne,” Journal of Investigative Dermatology, vol. 135, no. 6, pp. 1491–1500, 2015.
View at: Publisher Site | Google Scholar
T. K. Lee, R. T. P. Poon, J. Y. Wo et al., “Lupeol suppresses cisplatin-induced nuclear factor- B activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model,” Cancer Research, vol. 67, no. 18, pp. 8800–8809, 2007.
View at: Publisher Site | Google Scholar
H. R. Siddique and M. Saleem, “Beneficial health effects of lupeol triterpene: A review of preclinical studies,” Life Sciences, vol. 88, pp. 302–306, 2011.
View at: Publisher Site | Google Scholar
M. Saleem, “Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene,” Cancer Letters, vol. 285, no. 2, pp. 109–115, 2009.
View at: Publisher Site | Google Scholar
C. W. Cho, D. S. Choi, M. H. Cardone, C. W. Kim, A. J. Sinskey, and C. Rha, “Glioblastoma cell death induced by asiatic acid,” Cell Biology and Toxicology, vol. 22, no. 6, pp. 393–408, 2006.
View at: Publisher Site | Google Scholar
M. F. N. Meeran, S. N. Goyal, K. Suchal, C. Sharma, C. R. Patil, and S. K. Ojha, “Pharmacological Properties, Molecular Mechanisms, and Pharmaceutical Development of Asiatic Acid: A Pentacyclic Triterpenoid of Therapeutic Promise,” Frontiers in Pharmacology, vol. 9, 2018.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2020 Luis M. Guamán-Ortiz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

984

Downloads

852

Citations